VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma - PubMed (original) (raw)
. 2002 Jul 15;62(14):4123-31.
Affiliations
- PMID: 12124351
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma
David O Bates et al. Cancer Res. 2002.
Abstract
Angiogenesis is essential for tumor growth. Vascular endothelial growth factor (VEGF) is the most potent growth factor of tumor neovasculature, has been shown to be up-regulated in every tumor studied thus far, and is correlated with tumor stage and progression. To determine whether specific VEGF splice variants were differentially expressed in renal cell carcinomas, 18 polar tumor samples were analyzed by reverse transcription-PCR using primers designed to differentiate between VEGF splice variants. Control tissue was derived from the opposite normal pole. An amplicon of length consistent with the previously described variant VEGF(148) was found in normal kidney tissue. Subsequent sequencing revealed a new VEGF isoform formed by differential splicing from the end of exon 7 into the 3' untranslated region of the mRNA. Cloning of this transcript showed that translation would result in a 165-amino acid peptide with an alternative terminal 6 amino acids, followed by a stop codon. We have termed this new isoform VEGF165b. This isoform was present in 17 of 18 normal kidney samples but only 4 of 18 cases from matched malignant tissue. VEGF165b was therefore expressed in a significantly higher proportion of normal tissue than malignant tissue from the same patients (P < 0.001). To determine the functional significance of this new isoform, we expressed the full-length protein in a heterologous expression system. Conditioned medium containing this isoform significantly and dose dependently inhibited VEGF165-mediated proliferation, migration of endothelial cells, and vasodilatation of mesenteric arteries. This novel isoform VEGF165b is therefore an endogenous inhibitory form of VEGF that is down-regulated in renal tumors and, therefore, may be anti-angiogenesis.
Similar articles
- Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer.
Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, Zeillinger R. Stimpfl M, et al. Clin Cancer Res. 2002 Jul;8(7):2253-9. Clin Cancer Res. 2002. PMID: 12114428 - The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo.
Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M, Bicknell R. Zhang HT, et al. Br J Cancer. 2000 Jul;83(1):63-8. doi: 10.1054/bjoc.2000.1279. Br J Cancer. 2000. PMID: 10883669 Free PMC article. - [Correlation of neovascularization and vascular endothelial growth factor in human renal cell carcinoma].
Sato K, Kato T. Sato K, et al. Gan To Kagaku Ryoho. 1997 Feb;24(4):389-94. Gan To Kagaku Ryoho. 1997. PMID: 9063473 Review. Japanese. - Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Rini BI, Rathmell WK. Rini BI, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):741s-746s. doi: 10.1158/1078-0432.CCR-06-2110. Clin Cancer Res. 2007. PMID: 17255303 Review.
Cited by
- The Roles of Angiogenesis in Malignant Melanoma: Trends in Basic Science Research over the Last 100 Years.
Dewing D, Emmett M, Pritchard Jones R. Dewing D, et al. ISRN Oncol. 2012;2012:546927. doi: 10.5402/2012/546927. Epub 2012 Jun 7. ISRN Oncol. 2012. PMID: 22720169 Free PMC article. - Aerocyte specification and lung adaptation to breathing is dependent on alternative splicing changes.
Fidalgo MF, Fonseca CG, Caldas P, Raposo AA, Balboni T, Henao-Mišíková L, Grosso AR, Vasconcelos FF, Franco CA. Fidalgo MF, et al. Life Sci Alliance. 2022 Oct 11;5(12):e202201554. doi: 10.26508/lsa.202201554. Life Sci Alliance. 2022. PMID: 36220570 Free PMC article. - SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity.
Gammons MV, Dick AD, Harper SJ, Bates DO. Gammons MV, et al. Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5797-806. doi: 10.1167/iovs.13-11634. Invest Ophthalmol Vis Sci. 2013. PMID: 23761094 Free PMC article. - The balance of proangiogenic and antiangiogenic VEGFA isoforms regulate follicle development.
McFee RM, Rozell TG, Cupp AS. McFee RM, et al. Cell Tissue Res. 2012 Sep;349(3):635-47. doi: 10.1007/s00441-012-1330-y. Epub 2012 Feb 10. Cell Tissue Res. 2012. PMID: 22322423 Free PMC article. Review. - Butyrate increases the formation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells.
Ciura J, Jagodziński PP. Ciura J, et al. Mol Biol Rep. 2010 Dec;37(8):3729-34. doi: 10.1007/s11033-010-0026-1. Epub 2010 Mar 7. Mol Biol Rep. 2010. PMID: 20213511
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases